Value of N-terminal pro-brain natriuretic peptide combined with soluble growth stimulation expressed gene 2 to hospitalization death and all-cause death in patients with heart failure
Value of N-terminal pro-brain natriuretic peptide combined with soluble growth stimulation expressed gene 2 to hospitalization death and all-cause death in patients with heart failure
Objective To review the value of N-terminal pro-brain natriuretic peptide(NT-proBNP)combined withsoluble growth stimulation expressed gene 2(sST2)to risk stratification of hospitalization death and 1-y all-cause death in patients with heart failure(HF).Methods HF patients(n=900)were chosen from People's Hospital of Haikou City from Mar.2019 to Dec.2022.The levels of NT-proBNP and sST2 were detected when patients admitted.The patients were followed up for 1 y,and end-point events were hospitalization death and 1-y all-cause death.Results Of all selected patients,there were 38 died during hospitalization and 139 died within 1 y.According to baseline median levels of sST2 and NT-proBNP,the patients were divided into group A(low NT-proBNP+low sST2),group B(high NT-proBNP+low sST2),group C(low NT-proBNP+high sST2)and group D(high NT-proBNP+high sST2).Compared with group C,in group B age,percentages of dilated cardiomyopathy(DCM)and estimated glomerular filtration rate(eCFR)＜60 ml/min·1.73 m2,left ventricular end-diastolic diameter(LVEDd)and blood sodium level increased significantly(P＜0.05),and percentages of atrial fibrillation(AF)and infection,and levels of left ventricular ejection fraction(LVEF),white blood cell count(WBC)and hemoglobin(Hb)decreased significantly(P＜0.05).The results of multi-factor Cox regression analysis showed that hospitalization death risk increased significantly in group D compared with group A(HR=4.515,95％CI:1.288～15.602,P=0.018).The risk of 1-y all-cause death was the highest in group D,which was 5.736 times higher than group A(95％CI:3.114～10.396,P＜0.001),followed by group B.Conclusion There are differences in clinical characteristics in HF patients with different levels of NT-proBNP and sST2.NT-proBNP combined with sST2 can be used to analyze the risk stratification of hospitalization death and 1-y all-cause death in HF patients.
维普
万方数据